Pharminent

Payers Weigh the Implications of Multigene Testing Coverage in New UCSF Study

FORT WASHINGTON, Pa., Feb. 15, 2017 /PRNewswire-USNewswire/ — Innovation in precision medicine has introduced an amalgam of testing options, of which hereditary cancer panels—multigene tests—are a major component. Additionally, the importance of inherited cancer genomics was further… http://www.prnewswire.com/news-releases/payers-weigh-the-implications-of-multigene-testing-coverage-in-new-ucsf-study-300407868.html

Filed under: Payer